REG - Indivior PLC - Board Committee Changes

IndiviorAnnouncement

29/09/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230929:nRSc0769Oa&default-theme=true

RNS Number : 0769O  Indivior PLC  29 September 2023

September 29, 2023

 

Board Committee Changes

 

Indivior PLC (the "Company") (LSE/NASDAQ: INDV) announces the following
changes to the structure and composition of its Board Committees effective
October 1, 2023. These changes are designed to fully align and support
Indivior's key strategic priorities:

 

·      The Nomination & Governance Committee has been renamed the
Compliance, Ethics & Sustainability Committee and will have responsibility
for the oversight of the Group's Global Integrity and Compliance Program and
approach to ethical, responsible and sustainable conduct. Mark Stejbach has
been appointed as a member and Chair of this Committee.

·    The nomination-related responsibilities currently undertaken by the
Nomination & Governance Committee will be transferred to a new Nomination
Committee which will have oversight of Board and Committee composition and
succession planning. This Committee comprises Graham Hetherington as Chair and
all Non-Executive Directors.

·    The Science & Policy Committee has been renamed the Science
Committee. This Committee has oversight of the Group's R&D strategy and
pipeline development. Policy matters, which previously fell under this
Committee's remit, will now become part of the Board's remit. There are no
changes to the membership of this Committee.

·    The Audit Committee has been renamed the Audit & Risk Committee
to better reflect the role it plays in the oversight of internal control and
risk management activities. There are no changes to the membership of this
Committee.

·    As previously announced, Jo Le Couilliard has been appointed as Chair
of the Remuneration Committee. In addition, Barbara Ryan has been appointed as
a member of this Committee.

 

Graham Hetherington, Chair, said 'These changes to the structure and
composition of the Committees reflect our active evaluation and optimization
of Board expertise to support Indivior's strategy to create long-term value
for stakeholders. They reflect our continued focus on developing innovative
treatments that meet patient needs, conducting our business with the highest
integrity and our commitment to sustainability'.

 

As previously announced, Daniel J. Phelan, Senior Independent Director and
Chair of the Remuneration Committee, and Lorna Parker, Non-Executive Director,
will step down from the Board on September 30, 2023. Also as previously
announced, Juliet Thompson has been appointed as Senior Independent Director
with effect from October 1, 2023.

 

For completeness, membership of all of the above Committees with effect from
October 1, 2023, isset out below:

 

Audit & Risk Committee

Juliet Thompson (Chair)

Joanna Le Couilliard

Barbara Ryan

Mark Stejbach

 

Compliance, Ethics & Sustainability Committee

Mark Stejbach (Chair)

Graham Hetherington

Jerome Lande

Tom McLellan

Juliet Thompson

 

Nomination Committee

Graham Hetherington (Chair)

Peter Bains

Jerome Lande

Joanna Le Couilliard

Tom McLellan

Barbara Ryan

Mark Stejbach

Juliet Thompson

 

Remuneration Committee

Joanna Le Couilliard (Chair)

Peter Bains

Graham Hetherington

Barbara Ryan

 

Science Committee

Peter Bains (Chair)

Tom McLellan

Barbara Ryan

Mark Stejbach

 

This announcement is made pursuant to Listing Rule 9.6.11.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in 39
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XV57BWLOjOnGhAQJWI0WKEK4%2FXf0M9QcOEiYwwerqho%3D&reserved=0)
 to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=ztGNJPoRRJvCmxgR2tqSP1oJuDdNpAGH7hPFUtuOHcA%3D&reserved=0)
.

 

 

Contact

 

Jason Thompson

Vice President, Investor Relations

Indivior PLC

+1 804 402 7123

jason.thompson@indivior.com

 

Tim Owens

Director, Investor Relations

Indivior PLC

+1 804 263 3978

timothy.owens@indivior.com

 

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAVVLFLXKLBBBV